Nicotinic acid: Recent developments

Current Opinion in Cardiology

Volumn 23, Issue 4, 2008, Pages 393-398

  Kamanna, Vaijinath S ^a,b   Vo, Anthony ^a,b   Kashyap, Moti L ^a,b,c  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

DP1 receptor; GPR109A; High density lipoproteins; Niacin; Niacin flush; Oxidative stress; Prostanoids; Triglyceride; Vascular inflammation

Indexed keywords

ACETYLSALICYLIC ACID; G PROTEIN COUPLED RECEPTOR; GPR 109A; LAROPIPRANT; NICOTINIC ACID; PLACEBO; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; TRIACYLGLYCEROL;

DRUG INHIBITION; DRUG MECHANISM; DRUG RELEASE; FLUSHING; HUMAN; LANGERHANS CELL; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANIMALS; CORONARY DISEASE; DYSLIPIDEMIAS; HUMANS; LIPID METABOLISM; NIACIN; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; VITAMIN B COMPLEX;

EID: 44649164508     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3283021c82     Document Type: Review

References (39)

1. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys 1955; 54:558-559.
2. Ganji SH, Zhang L-H, Kamanna VS, Kashyap ML. Effect of niacin on lipoproteins and atherosclerosis. Future Lipidol 2006; 1:549-557.
3. Myers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol 2004; 15:659-665.
4. Carlson LA. Nicotinic acid: the broad spectrum lipid drug. A 50th anniversary review. J Intern Med 2005; 258:94-114.
5. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:1582-1592.
6. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER 2). A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statin. Circulation 2004; 110:3512-3517.
7. Taylor AJ, Lee HJ, Sullenberger LE, et al. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006; 22:2243-2250.
8. Vittone F, Chait A, Morse JS, et al. Niacin plus simvastatin reduces coronary stenosis progression among patients with metabolic syndrome despite a modest increase in insulin resistance: a subgroup analysis of the HDL-atherosclerosis treatment study. J Clin Lipidol 2007; 1:203-210. This study demonstrated that chronic use of niacin and simvastatin retards the progression of atherosclerotic cardiovascular disease in patients with dysmetabolic syndrome, suggesting that the overall cardiovascular benefits outweigh the modest adverse effects on insulin resistance and glucose metabolism.
9. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 2004; 164:697-705.
10. Benyo Z, Gille A, Kero J, et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 2005; 115:3634-3640.
11. Benyo Z, Gille A, Benett C, et al. Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol Pharm 2006; 70:1844-1849.
12. Vaccari CS, Hammoud RA, Nagamia SH, et al. Revisiting niacin: reviewing the evidence. J Clin Lipidol 2007; 1:248-255.
13. Cefali EA, Simmons PD, Stanek EJ, et al. Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation. Int J Clin Pharmacol Ther 2006; 44:633-640.
14. Cefali EA, Simmons PD, Stanek EJ, et al. Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. Int J Clin Pharmacol Ther 2007; 45:78-88. This study described the beneficial effects of aspirin in further reducing niacin flush in patients treated with newly optimized extended-release niacin.
15. Cheng K, Wu T, Wu KK, et al. Antagonism of the prostaglandin D2 receptor1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A 2006; 103:6682-6687.
16. Lai E, DeLepepeire I, Crumley TM, et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther 2007; 81:849-857. This study examined the effect of DP1 receptor antagonist on niacin flush.
17. MacCubbin DL, Michel Y, Sirah W, et al. Lipid-altering efficacy and tolerability of extended-release niacin/laropiprant in patients with dyslipidemia. Poster presentation. In: 2007 European Society of Cardiology Annual Meeting; 1-5 September 2007; Vienna, Austria: European Society of Cardiology; 2007.
18. MacCubin D, Sirah W, Betteridge A, et al. Flushing profile of ER niacin/laropiprant in patients with primary hypercholesterolemia or mixed dyslipidemia. Poster presentation. In: 2007 AHA Scientific Sessions; 4-7 November 2007; Orlando, Florida: AHA; 2007.
19. Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its antilipolytic effect. Nat Med 2003; 9:352-355.
20. Wise A, Foord SM, Fraser NJ, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003; 278:9869-9874.
21. Soga T, Kamohara M, Takasaki J, et al. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 2003; 303:364-369.
22. Ganji SH, Tavintharan S, Zhu D, et al. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 2004; 45:1835-1845.
23. Jin FY, Kamanna VS, Kashyap ML. Niacin accelerates intracellular apo B degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (Hep G2) cells. Arterioscler Thromb Vasc Biol 1999; 19:1051-1059.
24. Carlson LA, Oro L. The effect of nicotinic acid on the plasma free fatty acids. Acta Med Scand 1962; 172:641-645.
25. Carlson LA. Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. Acta Med Scand 1963; 173:719-722.
26. Blum CB, Levy RI, Eisenberg S, et al. High density lipoprotein metabolism in man. J Clin Invest 1977; 60:795-807.
27. Shepherd J, Packard CJ, Patsch JR, et al. Effect of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 1979; 63:858-867.
28. Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implications for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997; 17:2020-2028.
29. Acton S, Riggoti A, Landschutz KT, et al. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996; 271:518-520.
30. Martinez LO, Jacquet S, Esteve JP, et al. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003; 421:75-79.
31. Zhang LH, Kamanna VS, Zhang MC, Kashyap ML. Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL. J Lipid Res 2008 [Epub ahead of print].
32. Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 2004; 67:411-419.
33. Ganji SH, Qin S, Liu Y, et al. Niacin inhibits LDL oxidation and redox-sensitive VCAM-1 and MCP-1 expression in human aortic endothelial cells [abstract]. Arterioscler Thromb Vasc Biol 2004; 24:E-125.
34. Kuvin JT, Dave DM, Sliney KA, et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 2006; 98:743-745.
35. Morrow JD, Parsons WG, Roberts LJ. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 1989; 38:263-274.
36. Benyo Z, Gille A, Bennett CL, et al. Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol Pharmacol 2006; 70:1844-1849.
37. Maciejewski-Lenoir D, Richman JG, Hakak Y, et al. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol 2006; 126:2637-2646.
38. Meyers CD, Liu P, Kamanna VS, Kashyap ML. Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush. Atherosclerosis 2007; 192:253-258. The study showing that niacin stimulates PGD2 secretion in macrophages may be useful in further identifying key regulators of PGD2 and other prostanoid production by niacin-related flush mechanisms.
39. Cheng K, Wu TJ, Sturino C, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci USA 2006; 103:6682-6687.